Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer

NCT00134069 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

NIH

Sponsor class

Conditions

Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage III Colon Cancer
Stage III Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer

Interventions

DRUG: sorafenib tosylate
DRUG: cetuximab
DRUG: irinotecan hydrochloride

Sponsor

National Cancer Institute (NCI)